Vascular Reactivity in Chronic Kidney Disease (CKD) Patients Receiving Paricalcitol Versus Placebo
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This research is studying how Vitamin D may affect blood vessels reaction to stress and blood
levels of substances that may increase blockages in the blood vessels in chronic kidney
disease (CKD) patients. Blood vessel health is worsened in CKD and some studies have shown
that Vitamin D improves blood vessel health. The type of Vitamin D being used in this study
(paricalcitol) is Food and Drug Administration (FDA) approved to treat high parathyroid
hormone levels. The purpose of this study is to find out if paricalcitol has other benefits
beyond its ability to lower parathyroid hormone levels such as improving the blood vessels
reaction to stress and decreasing blood levels of substances that may increase blockages in
the blood vessels.